Skip to main content
Top
Published in: Abdominal Radiology 2/2010

01-04-2010

Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience

Authors: Chan Kyo Kim, Byung Kwan Park, Won Park, Sam Soo Kim

Published in: Abdominal Radiology | Issue 2/2010

Login to get access

Abstract

The purpose of this study was to retrospectively assess the diagnostic performance of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced imaging (DCEI) at 3T in predicting locally recurrent prostate cancer after radiation therapy. Twenty-four patients with a rising prostate-specific antigen level after treatment with radiation therapy underwent prostate MR imaging at 3T, followed by transrectal ultrasound-guided biopsy. MRI findings and biopsy results were correlated in six prostate sectors of both peripheral zones. Two radiologists in consensus reviewed the MR images and rated the likelihood of recurrent cancer on a 5-point scale. Out of the 144 prostate sectors, 37 (26%) sectors were positive for cancer in ten patients. For predicting locally recurrent cancer, the sensitivity and specificity of DWI, DCEI, and combined DCEI and DWI were higher than those for T2-weighted imaging (T2WI). The accuracy of DWI, DCEI and combined DCEI and DWI was greater than that of T2WI. A significantly greater Az was determined for combined DCEI and DWI (Az = 0.863, P < 0.05) as compared with T2WI, DCEI, and DWI. For predicting locally recurrent prostate cancer after radiation therapy, our preliminary results suggest that the use of either DWI or DCEI is superior to the use of T2WI.
Literature
1.
go back to reference Shipley WU, Thames HD, Sandler HM, et al. (1999) Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. Jama 281:1598–1604CrossRefPubMed Shipley WU, Thames HD, Sandler HM, et al. (1999) Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. Jama 281:1598–1604CrossRefPubMed
2.
go back to reference Lee WR, Moughan J, Owen JB, Zelefsky MJ (2003) The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. Cancer 98:1987–1994CrossRefPubMed Lee WR, Moughan J, Owen JB, Zelefsky MJ (2003) The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. Cancer 98:1987–1994CrossRefPubMed
3.
go back to reference Grado GL, Collins JM, Kriegshauser JS, et al. (1999) Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 53:2–10CrossRefPubMed Grado GL, Collins JM, Kriegshauser JS, et al. (1999) Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 53:2–10CrossRefPubMed
4.
go back to reference Stephenson AJ, Scardino PT, Bianco FJ, Jr, Eastham JA (2004) Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy. Curr Treat Options Oncol 5:357–365CrossRefPubMed Stephenson AJ, Scardino PT, Bianco FJ, Jr, Eastham JA (2004) Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy. Curr Treat Options Oncol 5:357–365CrossRefPubMed
5.
go back to reference Shekarriz B, Upadhyay J, Pontes JE (2001) Salvage radical prostatectomy. Urol Clin North Am 28:545–553CrossRefPubMed Shekarriz B, Upadhyay J, Pontes JE (2001) Salvage radical prostatectomy. Urol Clin North Am 28:545–553CrossRefPubMed
6.
go back to reference Boccon-Gibod L, Djavan WB, Hammerer P, et al. (2004) Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 58:382–390CrossRefPubMed Boccon-Gibod L, Djavan WB, Hammerer P, et al. (2004) Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 58:382–390CrossRefPubMed
7.
go back to reference Coakley FV, Hricak H, Wefer AE, et al. (2001) Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 219:817–821PubMed Coakley FV, Hricak H, Wefer AE, et al. (2001) Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 219:817–821PubMed
8.
go back to reference Rouviere O, Valette O, Grivolat S, et al. (2004) Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor—correlation with biopsy findings. Urology 63:922–927CrossRefPubMed Rouviere O, Valette O, Grivolat S, et al. (2004) Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor—correlation with biopsy findings. Urology 63:922–927CrossRefPubMed
9.
go back to reference Pucar D, Shukla-Dave A, Hricak H, et al. (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 236:545–553CrossRefPubMed Pucar D, Shukla-Dave A, Hricak H, et al. (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 236:545–553CrossRefPubMed
10.
go back to reference Heijmink SW, Scheenen TW, Futterer JJ, et al. (2007) Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy. Invest Radiol 42:420–427CrossRefPubMed Heijmink SW, Scheenen TW, Futterer JJ, et al. (2007) Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy. Invest Radiol 42:420–427CrossRefPubMed
11.
go back to reference Sala E, Akin O, Moskowitz CS, et al. (2006) Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 238:929–937CrossRefPubMed Sala E, Akin O, Moskowitz CS, et al. (2006) Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 238:929–937CrossRefPubMed
12.
go back to reference Pickett B, Kurhanewicz J, Coakley F, et al. (2004) Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60:1047–1055CrossRefPubMed Pickett B, Kurhanewicz J, Coakley F, et al. (2004) Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60:1047–1055CrossRefPubMed
13.
go back to reference Futterer JJ, Scheenen TW, Heijmink SW, et al. (2007) Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 42:116–122CrossRefPubMed Futterer JJ, Scheenen TW, Heijmink SW, et al. (2007) Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 42:116–122CrossRefPubMed
14.
go back to reference Kim CK, Park BK (2008) Update of prostate magnetic resonance imaging at 3 T. J Comput Assist Tomogr 32:163–172CrossRefPubMed Kim CK, Park BK (2008) Update of prostate magnetic resonance imaging at 3 T. J Comput Assist Tomogr 32:163–172CrossRefPubMed
15.
go back to reference Tanenbaum LN (2006) Clinical 3T MR imaging: mastering the challenges. Magn Reson Imaging Clin N Am 14:1–15CrossRefPubMed Tanenbaum LN (2006) Clinical 3T MR imaging: mastering the challenges. Magn Reson Imaging Clin N Am 14:1–15CrossRefPubMed
16.
go back to reference Manenti G, Carlani M, Mancino S, et al. (2007) Diffusion tensor magnetic resonance imaging of prostate cancer. Invest Radiol 42:412–419CrossRefPubMed Manenti G, Carlani M, Mancino S, et al. (2007) Diffusion tensor magnetic resonance imaging of prostate cancer. Invest Radiol 42:412–419CrossRefPubMed
17.
go back to reference Kim CK, Park BK, Lee HM, Kwon GY (2007) Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol 42:842–847CrossRefPubMed Kim CK, Park BK, Lee HM, Kwon GY (2007) Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol 42:842–847CrossRefPubMed
18.
go back to reference American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035–1041 American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035–1041
19.
go back to reference Huisman HJ, Engelbrecht MR, Barentsz JO (2001) Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging 13:607–614CrossRefPubMed Huisman HJ, Engelbrecht MR, Barentsz JO (2001) Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging 13:607–614CrossRefPubMed
20.
go back to reference Kim CK, Park BK, Kim B (2006) Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. J Comput Assist Tomogr 30:7–11CrossRefPubMed Kim CK, Park BK, Kim B (2006) Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. J Comput Assist Tomogr 30:7–11CrossRefPubMed
21.
go back to reference Futterer JJ, Heijmink SW, Scheenen TW, et al. (2006) Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241:449–458CrossRefPubMed Futterer JJ, Heijmink SW, Scheenen TW, et al. (2006) Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241:449–458CrossRefPubMed
22.
go back to reference Schaefer PW, Grant PE, Gonzalez RG (2000) Diffusion-weighted MR imaging of the brain. Radiology 217:331–345PubMed Schaefer PW, Grant PE, Gonzalez RG (2000) Diffusion-weighted MR imaging of the brain. Radiology 217:331–345PubMed
23.
go back to reference Lichy MP, Aschoff P, Plathow C, et al. (2007) Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping-Initial Clinical Experiences in Comparison to PET-CT. Invest Radiol 42:605–613CrossRefPubMed Lichy MP, Aschoff P, Plathow C, et al. (2007) Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping-Initial Clinical Experiences in Comparison to PET-CT. Invest Radiol 42:605–613CrossRefPubMed
24.
go back to reference Schaefer PW, Ozsunar Y, He J, et al. (2003) Assessing tissue viability with MR diffusion and perfusion imaging. AJNR Am J Neuroradiol 24:436–443PubMed Schaefer PW, Ozsunar Y, He J, et al. (2003) Assessing tissue viability with MR diffusion and perfusion imaging. AJNR Am J Neuroradiol 24:436–443PubMed
25.
go back to reference Abdel Razek AA, Kandeel AY, Soliman N, et al. (2007) Role of diffusion-weighted echo-planar MR imaging in differentiation of residual or recurrent head and neck tumors and posttreatment changes. AJNR Am J Neuroradiol 28:1146–1152CrossRefPubMed Abdel Razek AA, Kandeel AY, Soliman N, et al. (2007) Role of diffusion-weighted echo-planar MR imaging in differentiation of residual or recurrent head and neck tumors and posttreatment changes. AJNR Am J Neuroradiol 28:1146–1152CrossRefPubMed
26.
go back to reference Hein PA, Eskey CJ, Dunn JF, Hug EB (2004) Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 25:201–209PubMed Hein PA, Eskey CJ, Dunn JF, Hug EB (2004) Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 25:201–209PubMed
27.
go back to reference Baur A, Huber A, Arbogast S, et al. (2001) Diffusion-weighted imaging of tumor recurrences and posttherapeutical soft-tissue changes in humans. Eur Radiol 11:828–833CrossRefPubMed Baur A, Huber A, Arbogast S, et al. (2001) Diffusion-weighted imaging of tumor recurrences and posttherapeutical soft-tissue changes in humans. Eur Radiol 11:828–833CrossRefPubMed
28.
go back to reference Takayama Y, Kishimoto R, Hanaoka S, et al. (2008) ADC value and diffusion tensor imaging of prostate cancer: changes in carbon-ion radiotherapy. J Magn Reson Imaging 27:1331–1335CrossRefPubMed Takayama Y, Kishimoto R, Hanaoka S, et al. (2008) ADC value and diffusion tensor imaging of prostate cancer: changes in carbon-ion radiotherapy. J Magn Reson Imaging 27:1331–1335CrossRefPubMed
29.
go back to reference Crook J, Malone S, Perry G, et al. (2000) Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 48:355–367PubMed Crook J, Malone S, Perry G, et al. (2000) Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 48:355–367PubMed
Metadata
Title
Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience
Authors
Chan Kyo Kim
Byung Kwan Park
Won Park
Sam Soo Kim
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 2/2010
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-008-9495-2

Other articles of this Issue 2/2010

Abdominal Radiology 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine